Scientists uncover thousands of previously missed proteins, many of which appear to be relevant to human health — including promising new targets for cancer immunotherapies.
The FDA cannot approve generic drugs for marketing until brand-name drug patents on its list expire or are successfully challenged, but courts have recently found that certain device-only patents are impermissible and should not be listed.
A scalable blueprint for postdoctoral training embeds entrepreneurial venture mechanics and industry mobility directly into academic infrastructure to cultivate ‘T-shaped’ scientific leaders.
A new generation of RNA therapies delivered by lipid nanoparticles takes aim at extrahepatic tissues.
